Journal Review: Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy-Article

Article

Pdf Summary

Subcutaneous immunoglobulin (SCIg) therapy is an alternative to intravenous immunoglobulin (IVIg) for treating chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg has comparable efficacy to IVIg but offers benefits like no venous access requirement, reduced adverse events, local-site reactions, and patient independence. Transitioning from IVIg to SCIg should be done after 1 week and dosing should be personalized. SCIg can improve quality of life due to convenience. Patient preferences, characteristics, and needs should be considered when choosing between SCIg and IVIg.

Keywords

Subcutaneous immunoglobulin therapy

SCIg

intravenous immunoglobulin therapy

IVIg

chronic inflammatory demyelinating polyneuropathy

CIDP

efficacy

venous access requirement

adverse events

patient independence

cidp

Chronic Inflammatory Demyelinating Polyneuropathy